Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.65 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479316 | 1.00 | MCHR1 (0.65) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4482386 | 0.92 | MCHR1 (0.54) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4482390 | 0.92 | MCHR1 (0.54) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4486878 | 0.92 | MCHR1 (0.77) | MCHR1CHRM1HTR2ACHRNB4CHRNA3 | |
| SCHEMBL4486874 | 0.92 | MCHR1 (0.77) | MCHR1CHRM1HTR2ACHRNB4CHRNA3 | |
| SCHEMBL4472146 | 0.90 | MCHR1 (0.68) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4472151 | 0.90 | MCHR1 (0.68) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4491992 | 0.87 | MCHR1 (0.83) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4483876 | 0.87 | MCHR1 (0.83) | MCHR1CHRM1HTR2ATLR7CHRNB4 | |
| SCHEMBL4483868 | 0.87 | MCHR1 (0.83) | MCHR1CHRM1HTR2ATLR7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 125/4885HTR2A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.